Related Experiment Video
Updated: May 15, 2026

09:30
Modeling Ligands into Maps Derived from Electron Cryomicroscopy
Published on: July 19, 2024
Structural Determination and Ligand Interaction of Macrophage Inhibitory Factor: A Standardized X-Ray Crystallography
Emmanuel K Yeboah1, Alessandro T Caputo2
1Immunity and Immune Evasion Laboratory, School of Health and Biomedical Sciences, RMIT University, Bundoora, VIC, 3083, Australia.
Methods in Molecular Biology (Clifton, N.J.)
|May 13, 2026
Summary
Determining macrophage migration inhibitory factor (MIF) crystal structures with ligands is key for drug discovery. This study presents a general method for MIF crystallization and structural analysis, aiding medicinal chemistry.
Area of Science:
- Structural biology
- Medicinal chemistry
- Protein crystallography
Background:
- Macrophage migration inhibitory factor (MIF) plays critical roles in inflammatory and immune responses.
- Understanding MIF-ligand interactions is essential for developing targeted therapeutics.
- Existing methods for MIF structural analysis are limited.
Purpose of the Study:
- To develop a versatile method for obtaining X-ray crystal structures of MIF bound to various ligands.
- To facilitate the study of MIF-ligand binding modes.
- To guide medicinal chemistry efforts in designing novel MIF inhibitors.
Main Methods:
- A generalized protocol for the crystallization of macrophage migration inhibitory factor (MIF).
- X-ray diffraction techniques for structural determination of MIF-ligand complexes.
- Structure-based drug design approaches.
Main Results:
- Successful crystallization of MIF using the described generic method.
- Determination of high-resolution X-ray crystal structures of MIF in complex with different ligands.
- Identification of key binding interactions within the MIF active site.
Conclusions:
- The presented method provides a robust platform for structural studies of MIF.
- This approach enables detailed analysis of MIF-ligand interactions, crucial for drug development.
- The findings will accelerate the discovery of novel therapeutics targeting MIF-related diseases.
